Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pivotal maternal GBS-NN/NN2 vaccine trial in pregnant women and infants
2026-525385-21-00Phase 3Authorised
- Sponsor
- MinervaX
- Start
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 25
01
Overview
Phase 3, randomised, single-blind trial in Streptococcus agalactiae infection (GBS) comparing GBS-NN/NN2 vaccine with Placebo (2 arms). Planned start Sep 2026; status: authorised.
02
Drugs
GBS-NN/NN2 vaccine
03
Conditions
Streptococcus agalactiae infection (GBS)
Beyond the preview
Go deeper on 2026-525385-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525385-21-00.